Autolus Therapeutics Plc (NASDAQ:AUTL) Q1 2021 Earnings Conference Call May 6, 2021 8:30 AM ET Company Participants Lucinda Crabtree - Vice President of Investor Relations Christian Itin - Chairman and Chief Executive Officer Andrew Oakley - Chief Financial Officer Conference Call Participants Mara Goldstein - Mizuho Matt Phipps - William Blair Gil Blum - Needham & Company Kelly Shi - Jefferies Asthika Goonewardene - Truist Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics First ...

Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2020 Earnings Conference Call March 4, 2021 8:30 AM ET Company Participants Lucinda Crabtree – Vice President-Investor Relations Christian Itin – Chairman and Chief Executive Officer Andrew Oakley – Chief Financial Officer Conference Call Participants Hannah Adeoye – JP Morgan Mara Goldstein – Mizuho Ingrid Gafanhão – Kempen Matt Phipps – William Blair Nick Abbott – Wells Fargo Biren Amin – Jefferies Operator Hello, ladies and gentlemen, and welcome to the Autolus T ...

Autolus Therapeutics PLC (NASDAQ:AUTL) Q3 2020 Earnings Conference Call November 5, 2020 8:30 AM ET Company Participants Lucinda Crabtree - VP, IR & Corporate Communications Christian Itin - Chairman & CEO Andrew Oakley - CFO & SVP Conference Call Participants James Birchenough - Wells Fargo Securities Gil Blum - Needham & Company Gabriel Fung - Mizuho Securities Graig Suvannavejh - Goldman Sachs Group Dingding Shi - Jefferies Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Thi ...

AUTO1 - Adult Acute Lymphoblastic Leukemia (ALL) - AUTO1 is designed for adult ALL patients, aiming for high activity, long persistence, and good tolerability [12, 13] - In a study with all patients, AUTO1 achieved a complete remission (CR) rate of 84%, and with a closed process, the CR rate was 92% [20] - At 6 months, the event-free survival (EFS) for all patients was 62%, and for those treated with the closed manufacturing process, it was 76% [20] - The company is on track for full data from the pivotal study AUTO1-AL1 by the end of 2021 [31] AUTO3 - Diffuse Large B Cell Lymphoma (DLBCL) - AUTO3, combined with pembrolizumab, demonstrated an overall response rate (ORR) of 65% and a complete response rate (CRR) of 48% across all dose levels [39] - At dose levels ≥ 150 x 10^6 cells, the ORR was 69% and the CRR was 56% [39] - At dose levels ≥ 150 x 10^6 with Day -1 pembro, the ORR was 75% and the CRR was 63% [39] - Notably, there were no Grade 3 or higher cytokine release syndrome (CRS) events observed at ≥ 150 x10^6 cell dose [35] Pipeline and Future Development - The company has a broad pipeline of next-generation programs designed to address limitations of current T cell therapies [8, 69] - Autolus plans to start Phase 1 trials for AUTO1NG, AUTO8 in H2 2020, and AUTO5, AUTO6NG, AUTO7 in 2021 [70, 95] - The company had $212 million cash on hand as of June 30, 2020 [97]

Autolus Therapeutics PLC (NASDAQ:AUTL) Q2 2020 Earnings Conference Call August 6, 2020 8:30 AM ET Company Participants Lucinda Crabtree - VP, IR & Corporate Communications Christian Itin - Chairman & CEO Andrew Oakley - CFO & SVP Conference Call Participants Mara Goldstein - Mizuho Securities Biren Amin - Jefferies Eric Joseph - JPMorgan Chase & Co. James Birchenough - Wells Fargo Securities Asthika Goonewardene - Truist Securities Robert Andrew - William Blair & Company Graig Suvannavejh - Goldman Sachs Gr ...

Clinical Program Updates - AUTO1 pivotal study in adult ALL was initiated in Q2 2020 as planned, with full data expected by the end of 2021[8, 9, 19] - AUTO3 continues to enroll patients in DLBCL study, with outpatient cohort initiated and next data update at ESMO in September 2020 and Q4 2020[8, 10] - AUTO4 Phase 1 clinical trial in TRBC1+ Peripheral TCL experienced enrollment pause due to COVID-19, with first data expected in H1 2021[8] - AUTO1NG in pALL and AUTO8 in multiple myeloma are on track to start Phase 1 in H2 2020[8] - AUTO5, AUTO6NG, and AUTO7 are expected to enter clinical development in 2021[8, 12] Corporate Highlights - Dr Jay T Backstrom was appointed to the Board of Directors[13] - Dr Nushmia Khokhar was promoted to Senior Vice President, Clinical Development[13] - Manufacturing capacity was extended at the Cell and Gene Therapy Catapult to secure initial commercial launch capability[13] Financial Overview - Cash balance as of June 30, 2020, was $212 million[33, 37] - Total operating expenses, net, for Q2 2020 were $39.5 million, compared to $37.2 million for Q2 2019[33] - Net loss for Q2 2020 was $32 million, compared to $28.5 million for Q2 2019[33]